Thursday, February 4, 2016

Carbylan's arthritis drug meets one amongst 2 main goals



Carbylan medical specialty Iraqi National Congress aforesaid its experimental drug to treat pain related to arthritis of the knee met {one of|one among|one in a veryll|one amongst|one in every of} its main goal in a late-stage trial.

However, the drug, Hydros-TA, didn't meet its second main goal, Carbylan aforesaid in a very statement.

The specialty pharmaceutical company's shares were up three.6 % at $2.56 in extended commerce on weekday.

No comments:

Post a Comment